735351-82-3

Usage

Uses

Used in Medicinal Chemistry:
1(2H)-Isoquinolinone, 6-bromo-3,4-dihydro-2-(phenylmethyl)is used as a compound in medicinal chemistry for its potential biological activity. The unique structure of the molecule allows it to interact with various biological targets, making it a promising candidate for the development of new drugs and therapies.
Used in Drug Development:
In the field of drug development, 1(2H)-Isoquinolinone, 6-bromo-3,4-dihydro-2-(phenylmethyl)is used as a starting material or a building block for the synthesis of novel pharmaceuticals. Its specific properties and potential interactions with biological targets can be exploited to design and develop new drugs with improved efficacy and selectivity.
Used in Research and Synthesis of Related Compounds:
1(2H)-Isoquinolinone, 6-bromo-3,4-dihydro-2-(phenylmethyl)is also used in research and the synthesis of other related compounds. Its unique structure and potential biological activity make it an interesting subject for further investigation, potentially leading to the discovery of new compounds with diverse applications in various fields.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, 1(2H)-Isoquinolinone, 6-bromo-3,4-dihydro-2-(phenylmethyl)is used as a key intermediate in the synthesis of various drugs and drug candidates. Its unique chemical properties and potential biological activities can be harnessed to develop new therapeutic agents with improved pharmacological profiles.
Used in Chemical Synthesis:
1(2H)-Isoquinolinone, 6-bromo-3,4-dihydro-2-(phenylmethyl)is used as a versatile building block in chemical synthesis, particularly for the preparation of complex organic molecules and natural products. Its unique structure and reactivity make it a valuable tool for synthetic chemists working on the development of new compounds with diverse applications.

Upstream product

• 147497-32-3 6-bromo-3,4-dihydroisoquinolin-1(2H)-one 
• 100-39-0 benzyl bromide 
• 1074-42-6 1-benzylaziridine 
• 299928-52-2 4-bromo-N-quinolin-8-ylbenzamide 

Downstream Products

• 735351-83-4 6-amino-2-benzyl-3,4-dihydro-2H-isoquinolin-1-one 

Relevant academic research and scientific papers

Nickel-Catalyzed Regio- And Stereospecific C-H Coupling of Benzamides with Aziridines

A nickel-catalyzed C-H coupling of 8-aminoquinoline-derived benzamides with aryl- and alkyl-substituted aziridines has been disclosed. The current strategy provides direct access to benzolactams by the C-H alkylation-intramolecular amidation cascade event with the concomitant removal of the aminoquinoline auxiliary. The regioselectivity of ring opening of aziridines can be controlled by the substituents. The reaction with chiral aziridines proceeds with inversion of configuration, thus suggesting an SN2-type nucleophilic ring-opening pathway.

NOVEL AMINE DERIVATIVE OR SALT THEREOF

A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents -COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.

Sulfonamide bicyclic compounds

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide (β-AP) production.

AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.